Merck & Cie
Records under this name other than the patents Merck & Cie holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 18 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,066,408 | Crystalline Binary Sodium Salts of 5-Methyl-(6S)-TETRAHYDROFOLIC Acid with Organic Bases now held by Merck Patent GmbH In force · High confidence | In force | High confidence | |
| US 7,727,987 | Crystalline Forms of ( 6R)-L-ERYTHRO-TETRAHYDROBIOPTERIN Dihydrochloride Term ended Term ended Oct 14, 2025 · High confidence | Term ended | Term ended Oct 14, 2025 | High confidence |
| US 9,771,368 | 18F-LABELLED Folates Lapsed on the fee record Ended Sep 26, 2025 · High confidence | Lapsed on the fee record | Ended Sep 26, 2025 | High confidence |
| US 8,318,745 | Crystalline Forms of (6R)-L-ERYTHRO-TETRAHYDROBIOPTERIN Dihydrochloride Term ended Term ended Nov 17, 2024 · High confidence | Term ended | Term ended Nov 17, 2024 | High confidence |
| US 8,344,139 | Process for Preparing Crystalline Polymorphic Forms of (6R)-L-ERYTHRO-TETRAHYDROBIOPTERIN Dihydrochloride Term ended Term ended Nov 17, 2024 · High confidence | Term ended | Term ended Nov 17, 2024 | High confidence |
| US 6,858,731 | Process for the Preparation of Pure Stereoisomers of Tetrahydrofolic Acid Ester Salts and Tetrahydrofolic Acid by Fractionated Crystallisation of Tetrahydrofolic Acid Ester Salts Term ended Term ended Jul 19, 2020 · High confidence | Term ended | Term ended Jul 19, 2020 | High confidence |
| US 7,816,525 | Process for the Preparation of Optically Pure Tetrahydropterins and Derivatives, and Specifically of Optically Pure Tetrahydrofolic Acid and Derivatives Thereof, by Stereospecific Hydrogenation Term ended Term ended Jul 12, 2020 · High confidence | Term ended | Term ended Jul 12, 2020 | High confidence |
| US 6,995,158 | Pharmaceutical Preparation Containing at Least Folic Acid or a Folate and Tetrahydrobiopterin (BH4) or Derivatives Thereof Used for the Treating or Preventing Cardiovascular or Neurological Disorders by Modulation of the Activity of Nitric Oxide Synthase (NOS) Term ended Ended no later than Jun 7, 2020 · Low confidence | Term ended | Ended no later than Jun 7, 2020 | Low confidence |
| 11/435,198 | Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate Abandoned Abandoned May 20, 2013 | Abandoned | Abandoned May 20, 2013 | |
| 11/938,688 | Pharmaceutical Composition Comprising Progestogens And/Or Estrogens and 5-Methyl-(6S)-TETRAHYDROFOLATE Abandoned Abandoned Mar 17, 2016 | Abandoned | Abandoned Mar 17, 2016 |